Guide

The site qualification visit

A site qualification visit is the sponsor’s or CRO’s on-site (or remote) evaluation of a clinical investigator and their site before the site is selected for a trial. Sponsors and CROs name it differently (pre-study visit, site selection visit, site evaluation visit), and some run it as two steps, an early selection visit and a fuller qualification visit. Under any name, this guide is about the evaluation done before the site is selected. The visit is how the sponsor satisfies itself, and later shows an auditor, that the investigator is qualified and the site can run the protocol. It is also, by design, a view of the site as the site presents it.

Why the visit happens

21 CFR 312.53 requires a sponsor to select only clinical investigators qualified by training and experience, and to obtain the investigator’s qualifications and commitments before the study begins. ICH E6 expects the sponsor to confirm that the investigator has adequate resources — time, staff, facilities, and eligible subjects — to conduct the trial properly. The qualification visit is the standard way to verify both, and its report is part of the evidence that the selection obligation was met. See clinical investigator selection for the wider process the visit belongs to.

What the visit covers

The clinical investigator. Qualifications and licensure, therapeutic-area experience, prior trial experience, personal availability for the study, and the investigator’s understanding of the protocol and their own responsibilities under the Form FDA 1572.

Staff and delegation. Sub-investigators and coordinators, their training and workload, the delegation plan, and turnover.

Patient population and enrollment. Access to eligible subjects, realistic enrollment projections, competing studies drawing on the same population, and the site’s enrollment record on comparable protocols.

Facilities and equipment. Exam and procedure space, laboratory access, calibrated equipment the protocol needs, and secure, temperature- controlled storage and accountability for the investigational product.

Records and systems. Source-document practices, electronic health record access for monitors, data-entry capacity, archiving, and how the site handles consent documentation.

Oversight. The IRB the site uses and its review timelines, the site’s SOPs, and its history of monitoring findings and audits it is willing to discuss.

Regulatory history. Usually one question — “Has the site been inspected by FDA, and how was each inspection classified?” — answered by the site.

What the visit cannot confirm

Everything above is assessed through the site: its staff, its documents, its answers. That is appropriate for capacity and capability, which only the site can demonstrate. It is a weaker basis for regulatory history, for three reasons that have nothing to do with anyone’s honesty.

FDA sends inspection findings to the clinical investigator, not typically to the sponsor. Unless the sponsor follows up independently, the site’s answer is the only account of the inspection the sponsor has.

The inspection may have been about someone else’s study. A large site runs several trials at once. An inspection two years ago on another sponsor’s protocol may not be what the coordinator thinks of when asked, and the clinical investigator is not required to report it unless a quality agreement says so.

Classification arrives late. FDA classifies an inspection weeks to months after it closes. A site can truthfully say “we were inspected and heard nothing” while an OAI is in review.

The FDA record fills the gap — whether FDA has inspected the clinical investigator, how each inspection was classified, what was cited, whether a warning letter followed, and whether the investigator appears in disqualification proceedings or on the debarment list — but it sits in separate FDA datasets and documents that do not share identifiers. Clinical Precedent assembles it into one record per clinical investigator and site. Reviewing that record before the visit turns the regulatory-history question from an open one into a specific one: “FDA cited case-history records in 2023 — can we see the 483 from that inspection and your responses and corrective action plans?” Asking the site for the Form FDA 483 from each inspection, during the pre-visit discussion or at the visit itself, is a reasonable request; knowing from the record which inspections to ask about makes it a targeted one.

Sequencing the check and the visit

The most useful order is record first, visit second. With the record assembled, the check takes minutes, costs nothing in travel, and shapes the visit: a record with no findings lets the visit concentrate on capacity; a record with findings gives the visit an agenda. Where the record shows a serious history, the sponsor’s options are to ask the site for their responses and corrective action plans, to visit with those findings in hand, or to choose a site without that history — and all three are cheaper before a visit is scheduled than after a site is activated.

Documenting the visit

The qualification visit report, the record check with its date, and the selection decision belong together in the site-selection file. Together they answer the question an inspector or auditor asks: how did the sponsor know this clinical investigator was qualified? A dated, documented answer — including one that finds no record — is the deliverable. That is what clinical investigator vetting produces for the record part of the file.

Questions this page answers

What is a site qualification visit?

It is the sponsor’s or CRO’s evaluation of a clinical investigator and site before the site is selected for a clinical trial: the investigator’s qualifications and availability, staff, patient population, facilities, investigational-product storage, records and IRB arrangements. Sponsors and CROs name it differently (pre-study visit, site selection visit, site evaluation visit), and some run it as two steps, an early selection visit and a fuller qualification visit.

Is a site qualification visit required by FDA?

FDA does not prescribe a visit by name. 21 CFR 312.53 requires the sponsor to select only clinical investigators qualified by training and experience and to obtain their qualifications before the study, and ICH E6 expects the sponsor to confirm the site has adequate resources. The qualification visit is the standard way to meet and document those expectations.

Does a site qualification visit reveal a site's FDA inspection history?

Only as the site reports it. FDA sends inspection findings to the clinical investigator, not typically to the sponsor, and an inspection is classified weeks to months after it closes. The FDA record — inspections, classifications, findings, warning letters and status lists — has to be reviewed independently, ideally before the visit.

What is the difference between a site qualification visit and a site initiation visit?

The qualification visit happens before selection and informs the decision to use the site. The site initiation visit comes after the site is selected, typically once the contract and IRB approval are in place; it trains the site on the protocol and procedures and is one of the last steps before the site is activated to enroll.

Can a site qualification visit be done remotely?

Often, yes, for much of the assessment; many sponsors combine a remote review with an on-site visit for facilities and investigational-product storage. The regulatory-history check does not depend on the visit format at all.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.